Florida Clinical Research Center, LLC Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Maitland FL United States (1998)
Status: Acquired by Meridien Research (2016)

Organization Overview

First Clinical Trial
2008
NCT00734435
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Clinical Research Center of Florida | Florida Clinical Research Center, Bradenton Florida | Florida Clinical Research Center, Maitland Florida

Active Ingredients

Drugs in Phase 4 Trials (3)

dexamethasone (1 trial)

loteprednol (lotemax) (1 trial)

olopatadine (patanol) (1 trial)

Drugs in Phase 3 Trials (1)

dexmecamylamine (2 trials)

Drugs in Phase 2 Trials (3)

centanafadine (1 trial)

olanzapine (zyprexa) (1 trial)

zonisamide (Zonegran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Disease (Phase 3)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Weight Gain (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7